Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 + Docetaxel/Prednisone in mCRPC
NCT02182622Phase 1Withdrawn
- Start
- Jul 2014
- Primary completion
- Dec 2015
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label trial of sonidegib in metastatic castration-resistant prostate cancer (mCRPC) (4 arms). Primary endpoint: Maximum Tolerated Dose at 42 days. Planned start Jul 2014; status: withdrawn.
02
Drugs
sonidegib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02182622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182622.